[ad_1]
International Center / Xu Peirong Report
In response to the new wave of epidemics caused by Wuhan pneumonia (COVID-19, new corona pneumonia) in various places, many countries have announced their approval to use the new corona vaccine. The Chinese government has also allowed people in some areas to administer the vaccine on their own. There are questions about the quality and safety, which means that even if it is free, you will not get vaccinated.
▲ The vaccine developed by Chinese pharmaceutical companies has been opened to the public. (Illustration / Pixabay)
According to a report by Radio Free Asia (RFA), due to the fact that the new corona vaccine is not covered by the health insurance payment, the price of the new corona vaccine varies widely from 400 to 8,000 yuan (around from NT $ 1,717 to 34,335), but one million Chinese are reported to be vaccinated.
The report noted that China’s vaccine management is chaotic, the casualties are endless, and inferior vaccines are often brought onto the market, leaving many people skeptical of the new domestically produced corona vaccine. A Guangzhou resident surnamed Zhao said during an interview that the community where he lives provides free vaccinations, but that he did not dare to go. Also, a woman surnamed Chen in Wuhan mentioned that a local dose of 2,700 yuan (about NT $ 11,590) Yuan), a total of 3 injections are required. Many people want to fight but don’t have the money to fight, and some members of medical staff told him not to get vaccinated because the clinical trial of the vaccine is not long enough.
Some people in Shanghai pointed out that family members work in medical institutions and the hospital has places for medical staff to administer vaccines, but no one dared to do so because there are still many doubts about the safety of the first batch of vaccines.
Chinese officials claimed that five candidate vaccines developed by four domestic pharmaceutical companies have entered the third phase of clinical trials. As the national epidemic has slowed, pharmaceutical companies have turned to other countries to search for subjects and get priority for vaccines or vaccine production technology. Terms of trade; It is understood that China is conducting final tests in at least 16 countries / regions.
Indonesia has received 1.2 million doses of the Beijing Sinovac Biotech vaccine earlier this month, and will carry out a large-scale vaccination plan; Pakistan also has high hopes for China’s vaccine, allocating US $ 150 million to the order in November. . However, some countries have adopted a more cautious attitude towards Chinese vaccines. A subject in Peru developed paralysis of the arm a few days ago. The Peruvian government immediately announced the suspension of clinical trials of the Sinopharm vaccine, the Brazilian Health Supervision Agency (Anvisa) said in a statement on the 15th. China’s criteria to approve the authorization of emergency use are not open or transparent, and it is impossible to know how the Chinese authorities decide to grant the authorization.
In Hong Kong, Executive Director Carrie Lam announced on the 11th that progress has been made in the procurement of new corona vaccines. The government has reached agreements with Kexing, BioNTech, Pfizer and AstraZeneca in the UK. Kexing’s first batch of 1 million doses will be delivered next month; the vaccine is provided by the SAR government for free, but people cannot choose which vaccine to administer.
